Yu Mi Wi

2.7k total citations
98 papers, 1.7k citations indexed

About

Yu Mi Wi is a scholar working on Molecular Medicine, Epidemiology and Infectious Diseases. According to data from OpenAlex, Yu Mi Wi has authored 98 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Medicine, 46 papers in Epidemiology and 35 papers in Infectious Diseases. Recurrent topics in Yu Mi Wi's work include Antibiotic Resistance in Bacteria (49 papers), Bacterial Identification and Susceptibility Testing (17 papers) and Antibiotics Pharmacokinetics and Efficacy (16 papers). Yu Mi Wi is often cited by papers focused on Antibiotic Resistance in Bacteria (49 papers), Bacterial Identification and Susceptibility Testing (17 papers) and Antibiotics Pharmacokinetics and Efficacy (16 papers). Yu Mi Wi collaborates with scholars based in South Korea, United States and Australia. Yu Mi Wi's co-authors include Kyong Ran Peck, Cheol‐In Kang, Doo Ryeon Chung, Kwan Soo Ko, Jae‐Hoon Song, Nam Yong Lee, Robin Patel, Si‐Ho Kim, Young Eun Ha and Jae‐Hoon Song and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Infectious Diseases and Scientific Reports.

In The Last Decade

Yu Mi Wi

94 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yu Mi Wi South Korea 26 724 588 510 268 264 98 1.7k
Nieves Larrosa Spain 26 789 1.1× 831 1.4× 462 0.9× 386 1.4× 262 1.0× 102 2.0k
Vikas Manchanda India 22 794 1.1× 559 1.0× 395 0.8× 331 1.2× 170 0.6× 74 1.8k
Alex Kallen United States 5 714 1.0× 629 1.1× 763 1.5× 186 0.7× 381 1.4× 8 1.9k
Axel Kola Germany 24 929 1.3× 463 0.8× 436 0.9× 402 1.5× 270 1.0× 66 2.0k
Diamantis P. Kofteridis Greece 27 732 1.0× 1.0k 1.7× 725 1.4× 264 1.0× 237 0.9× 107 2.4k
Rosy Reynolds United Kingdom 24 539 0.7× 609 1.0× 611 1.2× 200 0.7× 471 1.8× 62 2.1k
Roland Jureen Singapore 27 766 1.1× 641 1.1× 806 1.6× 360 1.3× 295 1.1× 78 2.1k
Özlem Kurt Azap Türkiye 19 944 1.3× 921 1.6× 378 0.7× 322 1.2× 178 0.7× 68 1.9k
Thaís Guimarães Brazil 26 520 0.7× 928 1.6× 995 2.0× 208 0.8× 172 0.7× 96 2.1k
A. Lefort France 25 518 0.7× 867 1.5× 858 1.7× 254 0.9× 284 1.1× 108 1.8k

Countries citing papers authored by Yu Mi Wi

Since Specialization
Citations

This map shows the geographic impact of Yu Mi Wi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Mi Wi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Mi Wi more than expected).

Fields of papers citing papers by Yu Mi Wi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Mi Wi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Mi Wi. The network helps show where Yu Mi Wi may publish in the future.

Co-authorship network of co-authors of Yu Mi Wi

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Mi Wi. A scholar is included among the top collaborators of Yu Mi Wi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Mi Wi. Yu Mi Wi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kim, Si‐Ho, et al.. (2025). Diagnostic performance of the direct stool Xpert Carba-R assay in active surveillance of carbapenemase-producing enterobacterales. Antimicrobial Resistance and Infection Control. 14(1). 121–121.
2.
3.
Lee, Hyeokjin, et al.. (2024). Resurgence of Pertussis in the Gyeongnam Region of South Korea in 2023 and 2024. Vaccines. 12(11). 1261–1261. 5 indexed citations
4.
Kim, Si‐Ho, Yu Mi Wi, & Kyong Ran Peck. (2023). Clinical Effectiveness of Tetracycline-Class Agents Based Regimens in Patients With Carbapenem-Resistant Acinetobacter baumannii Bacteremia: A Single-Center Retrospective Cohort Study. Journal of Korean Medical Science. 38(34). e263–e263. 2 indexed citations
5.
Eom, Joong Sik, Jae‐Hoon Ko, Kyong Ran Peck, et al.. (2023). Clinical Characteristics and Risk Factors for Mortality in Critical COVID-19 Patients Aged 50 Years or Younger During Omicron Wave in Korea: Comparison With Patients Older Than 50 Years of Age. Journal of Korean Medical Science. 38(28). e217–e217. 5 indexed citations
6.
Wi, Yu Mi, Ki Tae Kwon, Si‐Ho Kim, et al.. (2023). Carbapenem Use in the Last Days of Life: A Nationwide Korean Study. Antibiotics. 12(6). 964–964. 1 indexed citations
7.
Wi, Yu Mi, Ki Tae Kwon, Soyoon Hwang, et al.. (2023). Use of Antibiotics Within the Last 14 Days of Life in Korean Patients: A Nationwide Study. Journal of Korean Medical Science. 38(9). e66–e66. 7 indexed citations
8.
Kim, Si‐Ho, Seongman Bae, Yu Mi Wi, et al.. (2022). Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study. Journal of Korean Medical Science. 37(18). e134–e134. 16 indexed citations
9.
10.
Ryu, Byung-Han, Sun In Hong, Hyungseok Kang, et al.. (2021). Clinical Features of Adult COVID-19 Patients without Risk Factors before and after the Nationwide SARS-CoV-2 B.1.617.2 (Delta)-variant Outbreak in Korea: Experience from Gyeongsangnam-do. Journal of Korean Medical Science. 36(49). e341–e341. 22 indexed citations
11.
Choi, Ji Young, et al.. (2021). Two Distinct Genotypes of KPC-2-Producing Klebsiella pneumoniae Isolates from South Korea. Antibiotics. 10(8). 911–911. 6 indexed citations
12.
Jang, Sukbin, et al.. (2020). Viral kinetics of SARS-CoV-2 over the preclinical, clinical, and postclinical period. International Journal of Infectious Diseases. 102. 561–565. 37 indexed citations
13.
Wi, Yu Mi & Robin Patel. (2018). Understanding Biofilms and Novel Approaches to the Diagnosis, Prevention, and Treatment of Medical Device-Associated Infections. Infectious Disease Clinics of North America. 32(4). 915–929. 73 indexed citations
14.
Wi, Yu Mi, Ji-Young Choi, Jiyoung Lee, et al.. (2017). Emergence of colistin resistance in Pseudomonas aeruginosa ST235 clone in South Korea. International Journal of Antimicrobial Agents. 49(6). 767–769. 36 indexed citations
15.
Kang, Cheol‐In, Yu Mi Wi, Doo Ryeon Chung, et al.. (2016). Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections. The Korean Journal of Internal Medicine. 32(1). 146–157. 8 indexed citations
16.
Wi, Yu Mi, June Myung Kim, Eun‐Jeong Joo, et al.. (2012). High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia. International Journal of Antimicrobial Agents. 40(2). 108–113. 21 indexed citations
17.
18.
Kim, Eun Seok, Eun-Jeong Joo, Young Eun Ha, et al.. (2009). Clinical characteristics of infective endocarditis caused by Staphylococcus aureus: A 12-year experience in a tertiary-care hospital. The Korean Journal of Internal Medicine. 76(3). 329–337. 4 indexed citations
19.
Cheong, Hae Suk, Cheol‐In Kang, Ki Tae Kwon, et al.. (2007). Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteraemia. Journal of Antimicrobial Chemotherapy. 60(6). 1355–1360. 34 indexed citations
20.
Ki, Hyun Kyun, Jiyoung Rhee, Yu Mi Wi, et al.. (2005). Usefulness of Cytomegalovirus (CMV) Antigenemia Assay after Liver Transplantation. Infection and Chemotherapy. 37(4). 199–207. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nieves Larrosa Breakdown of academic impact, for papers by Vikas Manchanda Breakdown of academic impact, for papers by Alex Kallen Breakdown of academic impact, for papers by Axel Kola Breakdown of academic impact, for papers by Diamantis P. Kofteridis Breakdown of academic impact, for papers by Rosy Reynolds Breakdown of academic impact, for papers by Roland Jureen Breakdown of academic impact, for papers by Özlem Kurt Azap Breakdown of academic impact, for papers by Thaís Guimarães Breakdown of academic impact, for papers by A. Lefort
Rankless by CCL
2026